Inhibikase Therapeutics (IKT) Revenue (2020 - 2023)
Historic Revenue for Inhibikase Therapeutics (IKT) over the last 4 years, with Q4 2023 value amounting to $1.0.
- Inhibikase Therapeutics' Revenue fell 9999.84% to $1.0 in Q4 2023 from the same period last year, while for Sep 2024 it was $1.0, marking a year-over-year decrease of 9999.97%. This contributed to the annual value of $260501.0 for FY2023, which is 11103.45% up from last year.
- Per Inhibikase Therapeutics' latest filing, its Revenue stood at $1.0 for Q4 2023, which was down 9999.84% from $79569.0 recorded in Q3 2023.
- In the past 5 years, Inhibikase Therapeutics' Revenue registered a high of $1.4 million during Q1 2021, and its lowest value of $1.0 during Q4 2023.
- In the last 4 years, Inhibikase Therapeutics' Revenue had a median value of $72045.0 in 2023 and averaged $261438.4.
- As far as peak fluctuations go, Inhibikase Therapeutics' Revenue skyrocketed by 316985.6% in 2022, and later tumbled by 9999.84% in 2023.
- Inhibikase Therapeutics' Revenue (Quarter) stood at $170416.0 in 2020, then crashed by 98.86% to $1944.0 in 2021, then surged by 3169.86% to $63566.0 in 2022, then plummeted by 100.0% to $1.0 in 2023.
- Its Revenue stands at $1.0 for Q4 2023, versus $79569.0 for Q3 2023 and $116410.0 for Q2 2023.